Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.

• Webinar to be hosted on Tuesday, March 21, 2023 at 12:00 p.m. ET, register here, or at the link below.
• Dr. Zoltan Szallasi will provide a high-level overview of synthetic lethality, why synthetic lethality has become a desired trait for drugs in oncology, and an in-depth look at how Lantern is leveraging the synthetic lethality of its drug candidate LP-184 for several solid tumor types.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR^® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on March 21, 2023 at 12:00 p.m. ET focusing on synthetic lethality, the unique and powerful mechanism of action behind Lantern’s drug candidates LP-184, LP-284, and LP-100.

The webinar will feature a leading expert on synthetic lethality in DNA damage repair (DDR) deficient tumors, Zoltan Szallasi, M.D., who serves joint appointments as group leader of the Translational Cancer Genomics Department at the Danish Cancer Society Research Center and as faculty of the Computational Health Informatics Program (CHIP) and Assistant Professor of Pediatrics at Boston Children's Hospital, which are affiliated with Harvard Medical School.

During the webinar, Dr. Szallasi will discuss a broad range of topics surrounding synthetic lethality, including: a brief history of synthetic lethality in oncology, how synthetic lethality is being leveraged to successfully treat cancers with DDR deficiencies, the promising potential of LP-184’s synthetic lethality for DDR deficient tumors, and the potential to combine LP-184 with FDA approved agents to enhance LP-184’s anti-tumor potency. Details on the webinar and how to register can be found below:

Virtual KOL Webinar Details:

• When: Tuesday, March 21, 2023 at 12:00 p.m. ET
• Webinar Length: 35 minutes
• Registration Link:
  
  https://us06web.zoom.us/webinar/register/WN_SRl6B_BrRi6SUX8XzJnTrQ
• A replay of the webinar will be available on Lantern’s website beginning on March 21, 2023.

About the Synthetic Lethality Mechanism of Action and LP-184:

In oncology drug development, synthetic lethality has become a highly desired capability for small molecules as it promotes the selective anti-tumor toxicity of cancer cells, while reducing potential side effects to normal cells. This mechanism of action can exploit vulnerabilities in cancer cells, known as DNA damage repair deficiencies, which are common in 25-30% of solid tumors. Using synthetic lethality, Lantern’s drug candidate LP-184 has demonstrated nanomolar potency across a comprehensive number of in vitro and in vivo preclinical models in solid tumors as well as adult and pediatric central nervous system cancers. Based on its synthetic lethality mechanism of action and strong preclinical results, Lantern is targeting advancing LP-184 to a first-in-human Phase 1 clinical trial in mid-2023.

About Lantern Pharma:

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR^® AI and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes.

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR^® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR^® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR^® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005141/en/